Researchers at the University of California, Davis have developed non-hallucinogenic compounds with clinically relevant therapeutic efficacy that promote neural growth and plasticity.

Researchers at the University of California, Davis have developed a class of compounds intended for the treatment of neurodegenerative diseases such as Alzheimer's by inhibiting DYRK1A kinase and modulating 5-HT2Rs.

MCFAs provide a synergistic bactericidal effect in combination with antibiotics and bacteriophages to effectively treat antibiotic-resistant bacterial infections.

Brief description not available

Brief description not available

Researchers at the University of California, Davis have developed a therapy that combines bioactive lipids with antiretroviral drugs to accelerate viral suppression and promote gut mucosal repair in HIV treatment.

Researchers at the University of California, Davis have developed a novel hybrid microbial-derived oxylipin and endocannabinoid-like molecule designed to enhance gut and brain health by improving barrier integrity, reducing inflammation, and providing neuroprotection.

Researchers at the University of California, Davis have developed a unique non-sacrificial synthetic peptide substrate designed to inhibit plasmin activity and prevent tumor progression and ascites formation in cancers characterized by elevated plasmin levels.

Researchers at the University of California, Davis have developed a method and composition that direct the growth of long, coronally oriented blood vessels in tissue grafts to improve vascularization and clinical transplant outcomes.

A novel non-invasive therapy combining pulsed laser and dual-frequency ultrasound for rapid and precise treatment of port-wine stains.

The invention describes a platform technology that increases MHC presentation of oncogene derived peptide neoantigens that do not normally occur in the cell.  The platform has already been used to identify a method of increasing KRAS G12 D/V derived peptide presentation on MHC- I.

The central hurdle in the clinical translation of mRNA-based medicine is the inherent toxicity of the delivery vehicle. Standard Lipid Nanoparticles (LNPs) rely on cationic ionizable lipids that carry a positive charge at a pH of approximately 7.4, triggering aggressive pro-inflammatory responses and complement activation.  UC Berkeley researchers have developed a novel class of lipids engineered to resolve the "charge-toxicity" trade-off in nucleic acid delivery. Unlike conventional ionizable lipids that maintain a problematic positive charge density at physiological levels, these quaternized ionizable lipids are specifically tuned to remain neutral or negatively charged at a pH of approximately 7.4. They only transition to a positively charged state in acidic environments, such as the endosome, ensuring that the payload is released exactly where it is needed without alerting the immune system during systemic circulation. 

The core innovation is a dosimetry-driven approach that determines the activity concentration of a radioisotope based on the distance between the cement surface and the target tissue, enabling predictable, volume‑independent radiation dosing.

A novel high-affinity peptide selectively inhibits the human Kv1.5 channel to safely treat and prevent atrial fibrillation by targeting atrial electrophysiology.

Methods for treating bone tumors or other target tissues using radioisotopes mixed into a matrix material, most commonly bone cement.

Autoimmune disorders such as ankylosing spondylitis are heavily linked to specific genetic human tissue types, particularly variations of the human leukocyte antigen B27. Traditional treatments for these debilitating conditions often rely on broad immunosuppression, which weakens a patient's entire immune defense and increases the risk of infections. To provide a more precise solution, UC Berkeley researchers have developed small-molecule ligands that selectively target and block a specific disease-associated variation of this allele, known as human leukocyte antigen B27:05. The therapeutic compounds feature a distinct three-part molecular architecture that includes a targeted binding group designed to fit securely into a specific molecular pocket, a flexible chemical linker, and a reactive group that forms a stable bond with a neighboring cysteine amino acid residue. By turning off only the specific genetic driver responsible for the autoimmune reaction, this technology opens the door to highly targeted therapies that treat the root cause of the disease while leaving the rest of the immune system fully functional.

A highly precise and efficient gene-editing tool designed to correct single-nucleotide DNA mutations responsible for genetic diseases.

Researchers at the University of California, Davis have developed a novel nanobody specific for WISP2 that restores skeletal stem cell function to treat bone loss and promote bone growth in age-related bone diseases.

Brief description not available

An innovative PEG hydrogel system covalently bound with insulin to safely and effectively prime mesenchymal stem cells (MSCs) and enhance their therapeutic potential in wound healing.

Brief description not available

Chronic and complex wounds represent a substantial clinical and economic burden, affecting more than 6.5 million individuals in the United States and accounting for annual healthcare expenditures exceeding $25 billion. These wounds, including those arising from trauma such as blast and burn injuries, frequently involve multiple tissue types—e.g., skin, bone, and nerve—and are often associated with delayed or incomplete closure. In certain severe trauma populations, complications such as heterotopic ossification, characterized by abnormal bone formation within soft tissue, are observed at elevated incidence. More broadly, recalcitrant wounds are characterized by impaired healing dynamics, including persistent inflammation, fibrosis, and aberrant tissue regeneration. There are barriers to effective recovery because current standards of care have several critical limitations. Most therapies are “reactive” rather than “proactive” and they fail to adapt to the wound’s shifting physiological state, such as fluctuating pH or oxygen levels. Conventional devices use rigid or semi-rigid components, and this mismatch does not conform to contoured or mobile areas like the heel or joints. Moreover, semi-flexible electronics often lose contact during patient movement, and this inconsistent contact leading to sub-therapeutic dosing and persistent inflammation. Bridging this gap requires conformal, bio-integrated systems capable of sustained contact and autonomous, responsive therapeutic delivery to overcome the stagnant healing dynamics of recalcitrant wounds.

Chronic and complex wounds present a massive challenge for both patients and the healthcare system. In the United States alone, over 6.5 million people struggle with these injuries. Recent clinical data suggests that treatment costs now exceed $30 billion dollars annually. These wounds often include diabetic foot ulcers, bedsores, and severe trauma from accidents or combat. These wounds rarely heal on their own because they frequently suffer from poor blood flow and stalled healing processes. In extreme cases such as combat-related amputations, patients may even develop heterotopic ossification, which is a specific complication where bone mistakenly grows inside soft muscle tissue, making the recovery process even harder. Standard wound care is often reactive rather than proactive. Doctors usually check a wound every few days or weeks and apply treatments that do not change until the next visit. While tools like vacuum-assisted healing or lab-grown skin have helped to a certain degree, they have major drawbacks, including too bulky or complicated to administer and use at home. Moreover, these do not address the biggest flaw in today's wound care in that it is essentially "blind" between doctor visits, so while your body’s chemistry can change over hours and days, the current standard of care remains stubbornly static. Recent clinical data shows that this lack of precision is more than just an inconvenience; it is a primary reason why chronic wounds stall.

A monoclonal antibody that selectively targets the NLRP3 pyrin domain to inhibit inflammasome activation in inflammasome-related diseases.

Brief description not available